Sponsor Dossier
Teva Pharma
Sponsor Dossier for Teva Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABIRATERONE-TEVA
- Brand: ACITRETIN-TEVA
- Brand: AJOVY
- Brand: APIXABAN-TEVA
- Brand: ARMODAFINIL-TEVA
- Brand: AUSTEDO
- Brand: AZACITIDINE-TEVA
- Brand: AZILECT
- Device (sponsor): Injector, medication/vaccine, syringe
About
Teva Pharma is an Australian Private Company with ABN 41169715664, registered in NSW. The entity is active and GST-registered from 2014.
Portfolio
Teva Pharma has 40 brands on the ARTG, of which 30 are indexable and 26 carry a Product Information document. 20 brands are PBS-listed, 8 have a PBAC outcome on record, and 5 have an AusPAR on record. Notable brands include ABIRATERONE-TEVA, ACITRETIN-TEVA, AJOVY, APIXABAN-TEVA, ARMODAFINIL-TEVA, AUSTEDO, AZACITIDINE-TEVA, AZILECT, BI-EASE, BRALTUS, COPAXONE, DASATINIB-TEVA.
Therapeutic focus
— Neurology: 13 brands — Oncology: 9 brands — Psychiatry: 5 brands — Respiratory: 4 brands — Haematology: 3 brands — Cardiology: 2 brands — Reproductive Health: 2 brands — Dermatology: 2 brands
PBS footprint
20 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2026-03-01, across 8 brands with a PBAC outcome on record. The latest AusPAR is 2024-08-14, across 5 brands with an AusPAR on record.